News & Updates
Showing Multidisciplinary articles
Showing

OS benefit of adjuvant osimertinib in resected EGFR-mutated NSCLC persists at 8th year
Adjuvant osimertinib continues to demonstrate an overall survival (OS) benefit over placebo in patients with resected EGFR-mutated (exon 19 del/L858R) non-small cell lung cancer (NSCLC), according to the 8-year exploratory analysis of the phase III ADAURA trial presented at WCLC 2026.

Tarlatamab – a new SoC in 2L SCLC
After decades of topotecan being the sole standard second-line (2L) treatment for small-cell lung cancer (SCLC) in most countries, tarlatamab’s efficacy and a favourable safety and tolerability profile vs chemotherapy (CT) have defined a new standard of care (SoC) for patients whose disease progressed on or after initial platinum-based CT, according to Dr Martin Wermke of the National Center for Tumor Diseases Dresden Early Clinical Trial Unit in Dresden, Germany, who spoke at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).







